Using Vitamin C and Cordyceps to Improve Life Quality in Terminal Pancreatic Cancer Patients
Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer
This study is testing if high-dose vitamin C combined with Cordyceps can help improve the quality of life for patients with terminal pancreatic cancer who haven't responded to chemotherapy.
Quick facts
| Phase | Phase2; Phase3 |
|---|---|
| Study type | Interventional |
| Enrollment | 50 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Fudan University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Shanghai) |
| Trial ID | NCT06598033 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of high-dose vitamin C combined with herbal medicine, specifically Cordyceps, in enhancing the quality of life for patients suffering from terminal stage metastatic pancreatic cancer who have not responded to chemotherapy. Given the severe side effects of conventional treatments, this approach aims to alleviate symptoms such as anemia, fatigue, and pain. Participants will be monitored for improvements in their overall well-being and quality of life metrics. The study includes patients aged 18 to 80 with confirmed metastatic pancreatic adenocarcinoma who have undergone at least two lines of treatment.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 to 80 with metastatic pancreatic adenocarcinoma who have experienced tumor progression after two lines of chemotherapy.
Not a fit: Patients with non-adenocarcinoma pancreatic diagnoses or severe digestive tract inflammation may not benefit from this study.
Why it matters
Potential benefit: If successful, this treatment could significantly improve the quality of life for patients with terminal pancreatic cancer.
How similar studies have performed: While some studies have explored the use of vitamin C in cancer treatment, this specific combination with Cordyceps for pancreatic cancer is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Ability to understand and the willingness to sign a written informed consent document. * Age ≥ 18 years and ≤ 80 years. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Histologically or cytologically confirmed metastatic pancreas adenocarcinoma. * Tumor progression after two lines of treatments. * Adequate organ performance based on laboratory blood tests. * Presence of at least of one measurable lesion in agreement to RECIST criteria. * The expected survival ≥ 1 months. * Women of childbearing potential and men must agree to use adequate contraception prior to study entry and for the duration of study participation. Exclusion Criteria: * • The diagnosis was confirmed by pathology as non-adenocarcinoma of pancreas. * Inflammation of the digestive tract, including pancreatitis, cholecystitis, cholangitis, etc. * Pregnant or nursing women. * Glucose-6-phosphate dehydrogenase (G6PD) deficiency. * Severe and uncontrollable accompanying diseases that may affect protocol compliance or interfere with the interpretation of results. * Renal insufficiency or dialysis * Other serious accompanying illnesses, which, in the researcher\'s opinion, could seriously adversely affect the safety of the treatment. * Patients who are unwilling or unable to comply with study procedures.
Where this trial is running
Shanghai
- Shanghai Cancer Center — Shanghai, China (Recruiting)
Study contacts
- Principal investigator: Guopei Luo, MD — Shanghai Cancer Center
- Study coordinator: Huanyu Xia, MD
- Email: xianhuanyu@fudanpci.org
- Phone: 86 21 64031446
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.